MBX Biosciences, Inc. Common Stock (MBX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -20.21M | -18.3M | -21.54M | -17.43M | -22.68M | -16.04M | -14.66M | -13.27M | -10.71M | -11.15M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 10.89% | -14.12% | -46.86% | -31.38% | -111.75% | -43.88% | - | - | - | - |
| Net Income | -23.52M | -22.06M | -21.62M | -19.41M | -23.88M | -15.59M | -18.14M | -15.86M | -12.34M | -8.84M |
| Depreciation & Amortization | -579K | 865K | 50K | -979K | 77K | 58K | 75K | 63K | 48K | 41K |
| Stock-Based Compensation | 5.48M | 2.66M | 2.25M | 1.94M | 1.84M | 1.49M | 1.19M | 919K | 1.62M | 1.02M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 98K | -1.33M | -702K | 101K | -1.31M | -1.37M | -560K | -414K | -478K | -506K |
| Working Capital Changes | -1.69M | 1.57M | -1.51M | 918K | 600K | -627K | 2.77M | 2.02M | 434K | -2.86M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 3.97M | -861K | -2.04M | 2.01M | -1.56M | 645K | 2.23M | 579K | 474K | -310K |
| Cash from Investing | -97.1M | -129.97M | 17.06M | 25.99M | 3.23M | -67.34M | -100.79M | -7.89M | 15.43M | -28.95M |
| Capital Expenditures | -437K | -793K | -399K | -707K | -30K | -92K | -57K | -452K | -273K | -55K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 1M | 5M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 87.44M | 438K | 187.82M | 1.33M | 4K | -132K | 235.81M | -1.76M | 183K | 19K |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 87.44M | 438K | 187.82M | 1.33M | 4K | 0 | 235.81M | -1.76M | 183K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | -132K | 0 | 0 | 0 | 19K |
| Net Change in Cash | -29.87M | -147.84M | 183.34M | 9.88M | -19.45M | -83.51M | 120.36M | -22.92M | 35.42M | -40.08M |
| Free Cash Flow | -20.64M | -19.09M | -21.93M | -18.14M | -22.71M | -16.13M | -14.72M | -13.72M | -10.98M | -11.2M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 9.08% | -18.38% | -49% | -32.2% | -106.76% | -44% | - | - | - | - |
| FCF per Share | -0.44 | -0.52 | -0.64 | -0.54 | -0.68 | -0.48 | -0.44 | -0.41 | -0.33 | -0.35 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.83x | 1.00x | 0.90x | 0.95x | 1.03x | 0.81x | 0.84x | 0.87x | 1.26x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |